suggested that YES1 might be a novel target for SCLC treatment, with the use of dasatinib and CH6953755, potent inhibitors targeting phospho‐YES1 and YES1, leading to substantial suppression of tumor growth. This evidence concerns the gene YES1 and small cell lung carcinoma.